ATE538388T1 - Inhibition von tristetraprolin zum schutz von herzerkrankungen - Google Patents

Inhibition von tristetraprolin zum schutz von herzerkrankungen

Info

Publication number
ATE538388T1
ATE538388T1 AT02787885T AT02787885T ATE538388T1 AT E538388 T1 ATE538388 T1 AT E538388T1 AT 02787885 T AT02787885 T AT 02787885T AT 02787885 T AT02787885 T AT 02787885T AT E538388 T1 ATE538388 T1 AT E538388T1
Authority
AT
Austria
Prior art keywords
tristetraproline
inhibition
heart disease
protect heart
protect
Prior art date
Application number
AT02787885T
Other languages
English (en)
Inventor
Franz-Werner Kluxen
Bernd Hentsch
Thomas Ehring
Marian Braendle
Joerg Hoheisel
Marcus Frohme
Dimitri Zubakov
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE538388T1 publication Critical patent/ATE538388T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT02787885T 2001-12-12 2002-11-30 Inhibition von tristetraprolin zum schutz von herzerkrankungen ATE538388T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01129564 2001-12-12
PCT/EP2002/013545 WO2003054541A2 (en) 2001-12-12 2002-11-30 Inhibition of tristetraproline for protection of the heart from cardiac injuries

Publications (1)

Publication Number Publication Date
ATE538388T1 true ATE538388T1 (de) 2012-01-15

Family

ID=8179511

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02787885T ATE538388T1 (de) 2001-12-12 2002-11-30 Inhibition von tristetraprolin zum schutz von herzerkrankungen

Country Status (17)

Country Link
US (2) US20050084860A1 (de)
EP (1) EP1454142B1 (de)
JP (1) JP2005512579A (de)
KR (1) KR20040068559A (de)
CN (1) CN1602427A (de)
AR (1) AR037788A1 (de)
AT (1) ATE538388T1 (de)
AU (2) AU2002352201B2 (de)
BR (1) BR0214832A (de)
CA (1) CA2470148C (de)
ES (1) ES2378228T3 (de)
HU (1) HUP0402153A2 (de)
MX (1) MXPA04005628A (de)
PL (1) PL369849A1 (de)
RU (1) RU2004121681A (de)
WO (1) WO2003054541A2 (de)
ZA (1) ZA200405449B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100012714A (ko) * 2008-07-29 2010-02-08 재단법인서울대학교산학협력재단 Ｒｎａ 분자와 단백질 사이의 상호작용을 조절하는 물질을동정하기 위한 분석 방법
WO2010129746A2 (en) 2009-05-06 2010-11-11 Curna, Inc. Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof
CN113777312B (zh) * 2021-09-03 2024-02-02 普十生物科技(北京)有限公司 乙肝抗体片段的制备方法、乙肝抗体片段、试剂盒及应用
CN118831080B (zh) * 2024-09-24 2024-11-22 上海交通大学医学院附属仁济医院 5-氧脯氨酸在制备预防或治疗心肌病的药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770209A (en) * 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
AU3130597A (en) * 1996-05-16 1997-12-05 Duke University Tristetraprolin
AU6638800A (en) * 1999-08-13 2001-03-13 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Ttp-related zinc finger domains and methods of use

Also Published As

Publication number Publication date
MXPA04005628A (es) 2004-12-06
EP1454142A2 (de) 2004-09-08
KR20040068559A (ko) 2004-07-31
WO2003054541A2 (en) 2003-07-03
AU2002352201A1 (en) 2003-07-09
AU2009201627B2 (en) 2012-09-06
AU2009201627A1 (en) 2009-05-21
EP1454142B1 (de) 2011-12-21
US20050084860A1 (en) 2005-04-21
RU2004121681A (ru) 2005-04-20
CA2470148C (en) 2015-03-17
CN1602427A (zh) 2005-03-30
BR0214832A (pt) 2004-08-31
PL369849A1 (en) 2005-05-02
ZA200405449B (en) 2005-06-20
JP2005512579A (ja) 2005-05-12
AU2002352201B2 (en) 2009-01-29
WO2003054541A3 (en) 2003-11-06
US20090104182A1 (en) 2009-04-23
HUP0402153A2 (hu) 2005-01-28
AR037788A1 (es) 2004-12-01
ES2378228T3 (es) 2012-04-10
CA2470148A1 (en) 2003-07-03

Similar Documents

Publication Publication Date Title
IS8913A (is) Afleiður 4-tetrazólýl-4-fenýlpiperidíns til þess að meðhöndla verk
IS2917B (is) Notkun breyttra sýklósporína til að meðhöndla HCV kvilla
EP1496894A4 (de) Angiogenese-hemmer
NO20044402L (no) Kombinasjonsbehandling av kemokine-medierte sykdommer
ATE344253T1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60121958D1 (de) Frühdiagnose von konformationellen erkrankungen
DE60043692D1 (de) Acyl derivate zur behandlung von krankheiten die in zusammenhang mit vla-4 stehen
ATE488224T1 (de) Aerosol-formulierungen von diisobutyryl apomorphine
NO20015112D0 (no) Anvendelse av glykosylceramidsynteseinhibitorer ved terapi
IS7851A (is) 1-asýl-pýrrólídínafleiður til að meðhöndla veirusýkingar
NO20044916L (no) Preparater av sulfinylacetamid
NO20020365D0 (no) Oligonukleotider for inhibering av ekspresjonen av humant EG5
EP1117431A4 (de) Behandlung von acidose
DE60103685D1 (de) Behandlung von Poriomania
EE200300502A (et) Katioonsete dekstraani derivaatide kasutamine annust piiravate elundite kaitsmiseks
DE60031450D1 (de) Polymorph v von torasemid
ATE463171T1 (de) Oberkörperprotektor zum schutz von personen vor kompressions trauma
DK1351697T3 (da) Lægemiddel til fremme af regenerationen af væv
ATE404203T1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression
DE60007111D1 (de) Herstellung von ausgewählten fluorolefinen
DE60308390D1 (de) Behandlung von Hyperurikämie
DE60336549D1 (de) Hepatoprotektor aktivität von 2'-p-hydroxybenzoylmussaenosidsäure
DE10211317A8 (de) Öko-Steamer nach Buck-Ufer
DE60326437D1 (de) Therapeutische verwendung von sapogeninen
EP1511474A4 (de) Behandlungsverfahren